SEC Form 4 · accession 0001209191-18-053533

Entasis Therapeutics Holdings Inc. · ETTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

10% Owner

10% Owner

Period of report

Sep 28, 2018

Accepted (ET)

Oct 2, 2018 · 9:35 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001724344

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Sep 28, 2018	C	1,918,185	—	A	1,918,189	I	See Footnote
Common Stock^F3	Sep 28, 2018	P	246,666	$15.00	A	2,164,855	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F3,F2	—	Sep 28, 2018	C	33,499,900	D	—	—	Common Stock	1,616,166	0	I

F1This number includes 302,019 shares of Common Stock received upon the conversion of the Issuer's Series A Preferred Stock as payment of accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.
F2Each share of Series A Preferred Stock automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.
F3All of these securities are owned by AstraZeneca AB, which is a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC may be deemed to beneficially own the shares held by AstraZeneca AB, but disclaims beneficial ownership except to the extent of its pecuniary interest therein, if any. The principal business address of AstraZeneca AB is SE-151 85 Sodertalje, Sweden.